JP2006510716A5 - - Google Patents

Download PDF

Info

Publication number
JP2006510716A5
JP2006510716A5 JP2004563615A JP2004563615A JP2006510716A5 JP 2006510716 A5 JP2006510716 A5 JP 2006510716A5 JP 2004563615 A JP2004563615 A JP 2004563615A JP 2004563615 A JP2004563615 A JP 2004563615A JP 2006510716 A5 JP2006510716 A5 JP 2006510716A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
chlorophenyl
aryl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004563615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510716A (ja
JP4719469B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/040040 external-priority patent/WO2004058145A2/en
Publication of JP2006510716A publication Critical patent/JP2006510716A/ja
Publication of JP2006510716A5 publication Critical patent/JP2006510716A5/ja
Application granted granted Critical
Publication of JP4719469B2 publication Critical patent/JP4719469B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004563615A 2002-12-19 2003-12-15 置換アミド類 Expired - Fee Related JP4719469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43543602P 2002-12-19 2002-12-19
US60/435,436 2002-12-19
PCT/US2003/040040 WO2004058145A2 (en) 2002-12-19 2003-12-15 Substituted amides

Publications (3)

Publication Number Publication Date
JP2006510716A JP2006510716A (ja) 2006-03-30
JP2006510716A5 true JP2006510716A5 (enExample) 2007-01-11
JP4719469B2 JP4719469B2 (ja) 2011-07-06

Family

ID=32682242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563615A Expired - Fee Related JP4719469B2 (ja) 2002-12-19 2003-12-15 置換アミド類

Country Status (9)

Country Link
US (2) US7348456B2 (enExample)
EP (1) EP1575901B1 (enExample)
JP (1) JP4719469B2 (enExample)
KR (1) KR20050088194A (enExample)
CN (1) CN1747926A (enExample)
AU (1) AU2003300967B2 (enExample)
CA (1) CA2510785C (enExample)
MX (1) MXPA05006728A (enExample)
WO (1) WO2004058145A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
JP2005528366A (ja) * 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
ES2294330T3 (es) 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
US7754188B2 (en) 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20100222316A1 (en) * 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
ATE555081T1 (de) * 2005-01-05 2012-05-15 Abbott Lab Adamantyl-derivate als inhibitoren des 11-beta- hydroxysteroid-dehydrogenase-1-enzyms
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN102816081A (zh) * 2005-01-05 2012-12-12 雅培制药有限公司 11-β-羟甾类脱氢酶1型酶的抑制剂
CA2606188A1 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
PL1902034T3 (pl) 2005-06-02 2011-09-30 Glenmark Pharmaceuticals Sa Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
KR20080027908A (ko) 2005-06-30 2008-03-28 프로시디온 리미티드 Ｇｐｃｒ 효능제
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
SI2114933T1 (sl) 2007-01-04 2012-01-31 Prosidion Ltd Windrush Court Piperidinski gpcr-agonisti
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
JP2010514832A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5736098B2 (ja) * 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1223388B (de) 1958-06-12 1966-08-25 Hoechst Ag Verfahren zur Herstellung von neuen Isonicotinsaeureamiden
DE1096883B (de) * 1959-09-25 1961-01-12 Basf Ag Verfahren zur Herstellung von festem Alkalisulfit
US3555093A (en) 1967-05-26 1971-01-12 Parke Davis & Co 2,alpha-dimenthyl-beta-ethyl-beta-(p-fluorophenyl)-ethylamines and the salts thereof
IE50355B1 (en) * 1979-10-20 1986-04-02 Wyeth John & Brother Ltd Morpholine derivatives
ZA852439B (en) * 1984-04-02 1986-04-30 Merck & Co Inc N-alkenyl-3-hydroxybenzo(b)thiophene-2-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US5281611A (en) * 1990-12-19 1994-01-25 Board Of Trustees Operating Michigan State University Euthanasia compositions
JPH07173120A (ja) * 1993-10-08 1995-07-11 Banyu Pharmaceut Co Ltd 置換芳香族カルボン酸誘導体
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
WO1998033765A1 (en) 1997-02-04 1998-08-06 E.I. Du Pont De Nemours And Company Fungicidal carboxamides
FR2764602B1 (fr) * 1997-06-11 1999-07-30 Oreal Composition cosmetique comprenant un amide et nouveaux amides
US6503905B1 (en) * 1998-12-29 2003-01-07 Pfizer Inc 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
DK1202986T3 (da) 1999-07-28 2006-02-20 Ortho Mcneil Pharm Inc Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
FR2804604B1 (fr) 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
GB2381313B (en) 2001-07-18 2005-01-05 Westerngeco Ltd A method of processing geophysical data
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EP1482794A1 (en) 2002-03-06 2004-12-08 Merck & Co., Inc. Method of treatment or prevention of obesity
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
JP2005528366A (ja) * 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
CA2479744A1 (en) * 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
WO2004103410A1 (en) * 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
ES2294330T3 (es) 2002-08-02 2008-04-01 MERCK & CO., INC. Derivados de furo(2,3-b)piridina sustituidos.
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
MY134457A (en) 2002-11-22 2007-12-31 Merck & Co Inc Substituted amides
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
UA83230C2 (ru) 2003-06-11 2008-06-25 Мерк Энд Ко., Инк. Замещенные производные 3-алкил- и 3-алкенилазетидинов
JP2007506654A (ja) 2003-06-20 2007-03-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｂ１受容体逆作動物質としての２−アミノベンゾチアゾール類
US7754188B2 (en) 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
AR045533A1 (es) 2003-09-02 2005-11-02 Solvay Pharm Gmbh Uso de un compuesto antagonista de receptor de cb1, composicion farmaceutica y metodo de tratamiento y/o profilaxis de enfermedades relacionadas con dicho receptor de cb1
EP1663215A1 (en) 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
EP1663113A4 (en) 2003-09-18 2007-06-13 Merck & Co Inc SUBSTITUTED SULFONAMIDE
RU2006117627A (ru) 2003-10-24 2007-12-10 Зольвай Фармасьютиклз Гмбх (De) Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений
US8166053B2 (en) 2003-10-30 2012-04-24 Ntt Docomo, Inc. Method and apparatus for schema-driven XML parsing optimization

Similar Documents

Publication Publication Date Title
JP2006510716A5 (enExample)
AU2023201399B2 (en) Modulators of the integrated stress pathway
TWI518080B (zh) 布魯頓氏酪胺酸激酶抑制劑
AU2018358157B2 (en) Modulators of the integrated stress pathway
CN109789146B (zh) 趋化因子受体调节剂及其用途
RU2459806C2 (ru) Замещенные гетероарильные производные
RU2412934C2 (ru) Применение антагонистов crth2 в терапии
CN101611013B (zh) 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物
DK2928474T3 (en) Diazollactamer
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
JP2023522250A (ja) 免疫活性化のためのｄｇｋｚｅｔａ阻害剤としての置換アミノチアゾール類
US20210169892A1 (en) Modulators of the integrated stress pathway
JP2008513498A5 (enExample)
JP2015529224A5 (enExample)
JP2020523330A (ja) シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト
TW200306837A (en) Adenosine A2a receptor antagonists
DK2935227T3 (en) DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS
JP2009538910A5 (enExample)
WO2007146761A2 (en) Diaryl pyrimidinones and related compounds
TW200900060A (en) Chemical compounds
AU2013364038A1 (en) Diazole amides
BRPI0411095B1 (pt) Derivados de imidazol, seus usos e seus processos de preparação, e medicamentos
TW200413369A (en) New compounds
CN119585256A (zh) 趋化因子受体调节剂及其用途
JP5101639B2 (ja) アミド誘導体及びそれを含有する医薬組成物